Recovery strategies following COVID-19 disruption to cervical cancer screening and their impact on excess diagnoses
Top Cited Papers
Open Access
- 9 February 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 124 (8), 1361-1365
- https://doi.org/10.1038/s41416-021-01275-3
Abstract
Background The COVID-19 pandemic has disrupted cervical cancer screening services. Assuming increases to screening capacity are unrealistic, we propose two recovery strategies: one extends the screening interval by 6 months for all and the other extends the interval by 36/60 months, but only for women who have already missed being screened. Methods Using routine statistics from England we estimate the number of women affected by delays to screening. We used published research to estimate the proportion of screening age women with high-grade cervical intraepithelial neoplasia and progression rates to cancer. Under two recovery scenarios, we estimate the impact of COVID-19 on cervical cancer over one screening cycle (3 years at ages 25–49 and 5 years at ages 50–64 years). The duration of disruption in both scenarios is 6 months. In the first scenario, 10.7 million women have their screening interval extended by 6 months. In the second, 1.5 million women (those due to be screened during the disruption) miss one screening cycle, but most women have no delay. Results Both scenarios result in similar numbers of excess cervical cancers: 630 vs. 632 (both 4.3 per 100,000 women in the population). However, the scenario in which some women miss one screening cycle creates inequalities—they would have much higher rates of excess cancer: 41.5 per 100,000 delayed for screened women compared to those with a 6-month delay (5.9 per 100,000). Conclusion To ensure equity for those affected by COVID-19 related screening delays additional screening capacity will need to be paired with prioritising the screening of overdue women.Keywords
Funding Information
- Cancer Research UK (C8162/A16892, C8162/A25356, C8162/A25356)
This publication has 11 references indexed in Scilit:
- The Impact of COVID-19 on Cancer Screening: Challenges and OpportunitiesJMIR Cancer, 2020
- Implementation of Early Detection Services for Cancer in India During COVID-19 PandemicCancer Control, 2020
- Prevalence of cervical disease at age 20 after immunisation with bivalent HPV vaccine at age 12-13 in Scotland: retrospective population studyBMJ, 2019
- Primary cervical screening with high risk human papillomavirus testing: observational studyBMJ, 2019
- What cervical screening is appropriate for women who have been vaccinated against high risk HPV? A simulation studyInternational Journal of Cancer, 2018
- Cervical Cancer Screening in Partly HPV Vaccinated Cohorts – A Cost-Effectiveness AnalysisPLOS ONE, 2016
- Age-Specific Effectiveness of the Finnish Cervical Cancer Screening ProgrammeCancer Epidemiology, Biomarkers & Prevention, 2012
- Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort studyBMJ, 2008
- Screening-Preventable Cervical Cancer Risks: Evidence From a Nationwide Audit in SwedenJNCI Journal of the National Cancer Institute, 2008
- Benefit of cervical screening at different ages: evidence from the UK audit of screening historiesBritish Journal of Cancer, 2003